91高清自产国产拍,无码免费A级毛片大全,日本欧美国产中文字幕,99re热视频这里只有精品视频首页

首页

400-620-6333

提交您使用阿拉丁产品的研究文章，就得100元奖励！立即访问我们的提交页面.

跳到内容

语言

切换导航

我的购物车

搜索

菜单

账号

设置

语言

Cemiplimab (anti-PD-1)

规格或纯度: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

种属反应性: Human
亚型: Human IgG4

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
C412010-1mg	1mg	期货
C412010-5mg	5mg	期货
C412010-10mg	10mg	期货

查看相关系列

programmed cell death 1 (CD279) Antibody

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Cemiplimab (anti-PD-1)
规格或纯度	Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
特异性	PDCD1
应用	ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt
反应种属	Human
偶联标记	Unconjugated

产品属性

抗体类型	Primary antibody
Format	Whole IgG
亚型	Human IgG4
轻链亚型	Kappa
SDS-PAGE	26.0 kDa (Light Chain) & 49.9 kDa (Heavy Chain), under reducing conditions; 169.6 kDa, under non-reducing conditions.
纯化方法	Protein A purified
来源	CHO supernatant
物理外观	Liquid
防腐剂	No
浓度	Lot by Lot
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	Store at -80℃ for 18 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息	1801342-60-8

数据库链接

IMGT/mAb-DB	846
Reactome Reaction	R-HSA-9679421
Reactome Drug	R-ALL-9679434

靶标

Target ID

2760

名称

programmed cell death 1 (CD279)

缩写名

PD-1

家族

Other immune checkpoint proteins

别名

KCa2.1

基因和蛋白信息

Species	Transmembrane Domains	Amino Acids	Chromosomal Location	Gene Symbol	Gene Name
Human	1	288	2q37.3	PDCD1	programmed cell death 1
Mouse	1	288	1 D	Pdcd1	programmed cell death 1
Rat	1	287	9q36	Pdcd1	programmed cell death 1

OMIM

600244 (Hs)

UniProtKB

Q15116 (Hs) , Q02242 (Mm)

Ensembl Gene

ENSG00000188389 (Hs) , ENSMUSG00000026285 (Mm) , ENSRNOG00000019043 (Rn)

RefSeq Nucleotide

NM_005018 (Hs) , NM_001106927 (Rn) , NM_008798 (Mm)

RefSeq Protein

NP_005009 (Hs) , NP_001100397 (Rn) , NP_032824 (Mm)

Entrez Gene

5133 (Hs) , 301626 (Rn) , 18566 (Mm)

Protein GI

167857792 (Hs) , 6679239 (Mm) , 157817590 (Rn)

CATH/Gene3D

2.60.40.10 (N/A)

ChEMBL Target

CHEMBL3307223 (Hs) , CHEMBL4630756 (Mm)

关联配体

Ligand ID	10090
名称	cemiplimab
别名	REGN-2810
类别	Antibody
学名	4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide
生物活性评价	Cemiplimab does not bind mouse PD-1 in vitro or in vivo, or rat PD-1 in vitro . The antibody blocks human PD-1/PD-L1 interaction with an IC₅₀ <1nM in an ELISA .
评价	Cemiplimab (REGN2810) is a fully human anti-PD-1 immuno-oncology biological therapeutic that was developed by Regeneron Pharmaceuticals . This antibody was produced using Regeneron's genetically engineered VelocImmune® mice which have humanized immunoglobulin gene loci and produce human:mouse hybrid antibodies that can rapidly be converted to fully human antibodies . Full peptide sequence and disulphide bond information is available from the IMGT/mAb-DB entry for this antibody.
配体家族	Immune checkpoint modulators
单字母多肽序列
三字母多肽序列
翻译后修饰
化学修饰
临床描述	This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies. To estimate the clinical benefit of cemiplimab monotherapy for patients with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC) (Groups 1 and 3) or with unresectable locally advanced CSCC (Group 2), or with advanced CSCC [metastatic (nodal or distal) or unresectable locally advanced] treated (Group 4) as measured by overall response rate (ORR), according to central review. The primary objectives of the study are: - To compare the overall survival (OS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 in ≥50% of tumor cells - To compare the progression-free survival (PFS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic NSCLC whose tumors express PD-L1 in ≥50% of tumor cells The key secondary objective of the study is to compare the objective response rate (ORR) of cemiplimab versus platinum-based chemotherapies
来源公司	Regeneron Pharmaceuticals Regeneron Pharmaceuticals Regeneron Pharmaceuticals

参考文献

1. Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, Huang TT, Poueymirou WT, Esau L, Meola M et al.. (2014) Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice.. Proc Natl Acad Sci USA, 111 (14): (5153-8). [PMID:24706856]
2. Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I, Fury MG. (2016) Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.. J Immunother Cancer, 4 (13): (70). [PMID:27879972]
3. Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al.. (2017) Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.. Mol Cancer Ther, 16 (5): (861-870). [PMID:28265006]
4. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS et al.. (2018) PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.. N Engl J Med, 379 (4): (341-351). [PMID:29863979]